Table 1.
Demographic and clinical characteristics by site of first metastasis in 389 patients with untreated primary breast cancer with distant metastasis.a
| -----Value or No. (%) of patients with metastasis----- | |||||
|---|---|---|---|---|---|
| Site of first metastasis | |||||
| Characteristic | Total patients | Bone only | Bone and other | Other only | p value (unadjusted)b |
| Total (%) | 389 | 72 (18.5) | 94 (24.2) | 223 (57.3) | |
| Age, years median (range) | 389 | 47 (23-70) | 46 (27-72) | 48 (25-74) | 0.80 |
| Sex | 0.70 | ||||
| Female | 386 | 72 (100) | 93 (99) | 221 (99.1) | |
| Male | 3 | 0 (0) | 1 (1) | 2 (0.9) | |
| Race/ethnicity | 0.59 | ||||
| Black | 36 | 4 (6) | 13 (14) | 19 (8.5) | |
| Hispanic | 39 | 9 (12) | 7 (7) | 23 (10.3) | |
| Other | 18 | 4 (6) | 4 (4) | 10 (4.5) | |
| White | 296 | 55 (76) | 70 (75) | 171 (76.7) | |
| Menopausal status | 0.48 | ||||
| Post | 165 | 33 (46) | 35 (37) | 97 (43.5) | |
| Pre | 187 | 36 (50) | 50 (53) | 101 (45.3) | |
| Unknown | 37 | 3 (4) | 9 (10) | 25 (11.2) | |
| Grade (Nottingham grading system) | <0.001 | ||||
| I | 7 | 3 (4) | 1 (1) | 3 (1.3) | |
| II | 128 | 36 (50) | 37 (40) | 55 (24.7) | |
| III | 239 | 31 (43) | 54 (57) | 154 (69.1) | |
| Unknown | 15 | 2 (3) | 2 (2) | 11 (4.9) | |
| Grade (Nottingham grading system) | <0.001 | ||||
| I or II | 135 | 39 (54) | 38 (40) | 58 (26.0) | |
| III | 239 | 31 (43) | 54 (58) | 154 (69.1) | |
| Unknown | 15 | 2 (3) | 2 (2) | 11 (4.9) | |
| Histology | 0.002 | ||||
| Ductal | 327 | 53 (73) | 79 (84) | 195 (87.4) | |
| Lobular | 31 | 12 (17) | 11 (12) | 8 (3.6) | |
| Other | 31 | 7 (10) | 4 (4) | 20 (9.0) | |
| IBC | 0.20 | ||||
| IBC | 34 | 8 (11) | 4 (4) | 22 (9.9) | |
| Non-IBC | 355 | 64 (89) | 90 (96) | 201 (90.1) | |
| HER2 status | 0.10 | ||||
| Negative | 354 | 68 (94) | 89 (95) | 197 (88.3) | |
| Positive | 35 | 4 (6) | 5 (5) | 26 (11.7) | |
| HR status | <0.001 | ||||
| Negative | 121 | 9 (12) | 22 (23) | 90 (40.4) | |
| Positive | 268 | 63 (88) | 72 (77) | 133 (59.6) | |
| TNBC status | <0.001 | ||||
| TNBC | 112 | 8 (11) | 22 (23) | 82 (36.8) | |
| Non-TNBC | 277 | 64 (89) | 72 (77) | 141 (63.2) | |
| Subtype | <0.001 | ||||
| HR-/HER2+ | 9 | 1 (2) | 0 (0) | 8 (3.6) | |
| HR+/HER2- | 242 | 60 (83) | 67 (71) | 115 (51.5) | |
| HR+/HER2+ | 26 | 3 (4) | 5 (5) | 18 (8.1) | |
| TNBC | 112 | 8 (11) | 22 (24) | 82 (36.8) | |
Abbreviations: HR, hormone receptor; IBC, inflammatory breast cancer; TNBC, triple-negative breast cancer.
aValues in table are number of patients (percentage) unless otherwise indicated.
bFor comparison between patients with bone-only and other-only metastases.